PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila(Vall d'Hebron Hospital Universitari), Matthew H. Taylor(Providence Portland Medical Center), Rodryg Ramlau(Poznan University of Medical Sciences), Jason E. Faris(Royal Marsden NHS Foundation Trust), Anna Wrona, Marie Luise Hütter‐Krönke(University Hospital Ulm), Sebastian Szpakowski(Novartis (United States)), Geraldine Bostel(Novartis (Switzerland)), Hans Gelderblom(Leiden University Medical Center), Lori J. Wirth(Harvard University), Andreea Varga(Institut Gustave Roussy), Jean‐Pierre Delord, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Chia‐Chi Lin(National Taiwan University Hospital), Thomas Ernst(Jena University Hospital), Hongqian Wu, Peter M. Sadow(Massachusetts Eye and Ear Infirmary), Patrick M. Forde(Johns Hopkins University), Angelica Fasolo, Armando Santoro(IRCCS Humanitas Research Hospital), Santiago Ponce Aix(Research Institute Hospital 12 de Octubre), Scott B. Cameron(Novartis (United States)), Dagmar Führer(University of Duisburg-Essen), Marcus O. Butler(University of Toronto)
Cited by 349
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k